If you are considering robotic prostate surgery, you may naturally want to know about your chances of long-term survival. Studies show very high prostate cancer-specific survival after robot-assisted radical prostatectomy, particularly when the cancer is localised or considered lower risk.
Your individual outlook depends on factors such as cancer stage, Grade Group, PSA level and whether lymph nodes are involved. Some studies report prostate cancer-specific survival of around 98–99% at 10 years, but survival can be lower with high-risk or advanced cancer.
What Does “Survival Rate” Mean After Prostate Cancer Surgery?
“Survival rate” can mean different things depending on what researchers are measuring. Prostate cancer-specific survival looks at deaths caused by prostate cancer, while overall survival includes deaths from any cause.
Other measures include metastasis-free survival, which looks at whether the cancer has spread, and biochemical recurrence-free survival, which considers PSA levels. A PSA recurrence does not necessarily mean the cancer has spread or will affect your long-term survival.
What Do Long-Term Robotic Prostatectomy Studies Show?
Several long-term studies provide useful information about survival after robot-assisted radical prostatectomy, although results vary because patients differed in cancer risk, age, treatment era and follow-up duration.
| Robotic prostatectomy study | Follow-up | Prostate cancer outcome | Overall survival | Metastatic outcome |
| 483-patient long-term robotic cohort | 10 years | Prostate cancer-specific survival: 98.8% | Not primarily reported | Metastasis-free survival: 97.5% |
| 1,807-patient robotic cohort | 15 years | Prostate cancer-specific mortality: 2.5% | 82.1% | Metastatic progression: 4.0% |
| Large multicentre European robotic study | 15 years | Prostate cancer-specific survival: 97.6% | 85.5% | Not primarily reported |
Long-term studies show very high cancer-specific survival after robotic prostatectomy, with rates of around 98% at 10 years and 97.6% at 15 years. Overall survival is lower, partly because other health conditions and ageing contribute to deaths.
Evidence Note
Long-term robotic prostatectomy studies are encouraging, but the reported percentages come from groups of patients treated at specialist centres and should not be interpreted as a guarantee for an individual patient. Cancer risk, pathological stage, Grade Group, PSA and other health factors can all influence your long-term outlook.
What Do UK Prostate Cancer Survival Statistics Show?
UK statistics show that around 95% of men with prostate cancer survive at least one year, 85% for five years and around 80% for 10 years or more. These figures cover all stages and treatments, so survival varies greatly depending on whether the cancer is localised or advanced.
| Prostate cancer stage at diagnosis | Five-year net survival in England |
| Stage 1 | Almost 100% |
| Stage 2 | Almost 100% |
| Stage 3 | Around 95% |
| Stage 4 | Around 50% |
These UK figures are based on men diagnosed between 2013 and 2017 and should not be confused with robotic prostatectomy survival rates. Because prostatectomy is generally offered to selected men with potentially curable localised or locally advanced disease, surgical cohorts are not directly comparable with population statistics that include men across all stages of prostate cancer.
What Does the UK ProtecT Trial Tell Us About Survival After Surgery?
The UK ProtecT trial included 553 men with localised prostate cancer who were randomly assigned to prostatectomy. At 15 years, prostate cancer-specific survival in the prostatectomy group was approximately 97.2%.
| ProtecT 15-year outcome | Prostatectomy group |
| Death from prostate cancer | 2.2% |
| Prostate cancer-specific survival | Approximately 97.2% |
| Developed metastases | 4.7% |
| Clinical progression | 10.5% |
| Required long-term hormone therapy | 7.2% |
| Death from any cause | 21.2% |
The ProtecT trial found metastases in 4.7% of men assigned to prostatectomy, compared with 9.4% with active monitoring. However, as the trial began in 1999 and did not specifically study modern robotic surgery, its 97.2% survival figure should be viewed as evidence for radical prostatectomy generally, rather than robotic surgery alone.
How Much Does Your Cancer Risk Group Affect Survival?
A 97–98% survival rate does not apply equally to everyone. Your long-term outlook depends partly on your cancer’s risk group at diagnosis, with robotic prostatectomy studies showing differences in 15-year prostate cancer-specific survival between lower- and higher-risk cancers.
| Risk group | 15-year prostate cancer-specific survival after robotic prostatectomy |
| Low risk | 99% |
| Intermediate risk | 98% |
| High risk | 90% |
Your cancer risk group can make a major difference to long-term survival. In one 15-year robotic study, prostate cancer mortality was around 1% for low-risk and 10% for high-risk disease, while another reported mortality of 0.5%, 3.4% and 6.6% for low-, intermediate- and high-risk groups respectively. This is why your individual prognosis is more useful than a single overall survival figure.
How Does Cancer Stage Affect Survival After Surgery?
Your cancer stage is an important factor in your long-term outlook after surgery. Cancer confined to the prostate is classified as pT2, while pT3a means it has spread outside the prostate and pT3b involves the seminal vesicles. Long-term robotic prostatectomy studies show that survival varies significantly between these stages.
| Final pathological stage | 15-year prostate cancer-specific survival |
| pT2 | 98.9% |
| pT3a | 97.4% |
| pT3b | 86.5% |
Survival can remain very high with pT3a disease but is generally lower with pT3b, where the cancer has reached the seminal vesicles. However, your prognosis also depends on factors such as grade, lymph nodes, surgical margins and postoperative PSA, so your final pathology provides a more personalised outlook.
How Does Prostate Cancer Grade Affect Long-Term Survival?
Your Grade Group provides important information about how aggressive your prostate cancer may be and can help your specialist assess your long-term outlook.
- Lower Grade Groups: Grade Group 1 generally represents less aggressive prostate cancer and is associated with a more favourable outlook.
- Higher Grade Groups: Higher Grade Groups indicate more aggressive cancer and are associated with a greater risk of recurrence or progression.
- Other Factors Matter: Grade Group should be considered alongside your PSA level, cancer stage, lymph-node status, surgical margins and postoperative PSA.
- Further Treatment May Be Needed: A higher Grade Group does not automatically rule out prostatectomy, but additional treatment may sometimes be recommended depending on your final pathology and PSA results.
Does Your PSA Level Affect Survival?
Your PSA level before surgery can provide important information about your prostate cancer risk. A higher PSA may be linked with a greater risk of recurrence, although PSA alone cannot show exactly how advanced your cancer is.
After radical prostatectomy, PSA becomes an important part of follow-up and is expected to become undetectable. A persistently detectable or subsequently rising PSA may indicate recurrence and should be interpreted alongside your pathology and PSA trend.
UK Guidance Note
NICE recommends checking PSA no earlier than six weeks after radical treatment, at least every six months for the first two years and at least once a year thereafter. Your follow-up schedule may be personalised according to your PSA results, cancer characteristics and individual circumstances.
Do Positive Surgical Margins Affect Survival?
A positive surgical margin means cancer cells are found at the edge of the tissue removed during surgery. You may have a higher risk of PSA recurrence, particularly when the margin is longer or present in several areas, but this does not automatically mean the cancer will spread or affect your survival.
Your specialist will consider the margin alongside your PSA, Grade Group and final cancer stage. If biochemical recurrence develops after prostatectomy, your specialist may discuss salvage treatment based on factors such as your PSA trend, pathology and whether there is evidence of metastatic disease.
What If Lymph Nodes or Seminal Vesicles Contain Cancer?
Seminal-vesicle or lymph-node involvement indicates higher-risk disease and can increase the likelihood of recurrence after prostatectomy. Studies show lower prostate cancer-specific survival when the seminal vesicles are involved.
Lymph-node involvement also increases your risk of recurrence, but it does not mean you cannot achieve long-term control. Your specialist may recommend additional treatment, such as radiotherapy or hormone therapy.
What Does Metastasis-Free Survival Tell You?
Metastasis-free survival shows whether your prostate cancer has spread to distant parts of your body after treatment. Long-term robotic prostatectomy studies report very high rates, including 97.5% at 10 years, although metastatic progression varies considerably according to your cancer risk.
| Pre-operative risk group | Metastatic progression by 15 years |
| Low risk | 1.1% |
| Intermediate risk | 4.1% |
| High risk | 13.0% |
At 15 years, metastatic progression was reported in 1.1% of low-risk, 4.1% of intermediate-risk and 13.0% of high-risk men in this cohort. These figures show how strongly baseline cancer risk can influence long-term metastatic progression after surgery. Your original cancer risk and any treatment after surgery, such as salvage radiotherapy or hormone therapy, can influence this outcome.
Is PSA Recurrence the Same as Poor Survival?
No. A rise in PSA after surgery does not mean you are immediately at risk of dying from prostate cancer. Long-term studies show that although around 27–28% of men may experience biochemical recurrence, most remain free from metastases and prostate cancer-specific death, with reported rates of 97.5% and 98.8% at 10 years.
| 15-year robotic outcome | Percentage experiencing event |
| Biochemical failure | 28.1% |
| Required secondary treatment | 16.3% |
| Metastatic progression | 4.0% |
| Death from prostate cancer | 2.5% |
PSA is a highly sensitive marker that can detect recurrent prostate cancer before symptoms or visible changes on scans. This can allow your medical team to consider further treatment early, so a biochemical recurrence should be monitored carefully but does not mean you have metastatic or terminal cancer.
Clinical Tip
If your PSA rises after prostatectomy, the level itself is only part of the picture. Your specialist may also consider how quickly PSA is increasing, your original Grade Group and stage, surgical pathology and whether imaging would change treatment decisions before recommending the next step.
Why Is Overall Survival Lower Than Prostate Cancer-Specific Survival?
You may see prostate cancer-specific survival of around 97–98%, while overall survival is closer to 82–86% after 15 years. This difference does not mean that people died because prostate surgery failed.
Overall survival includes deaths from every cause, including heart disease, stroke, other cancers and age-related conditions. Your age and general health can therefore affect overall survival, while cancer-specific survival gives you a clearer picture of how well the prostate cancer itself has been controlled.
Is Robotic Surgery More Effective for Survival Than Other Treatments?
You should not assume that robotic surgery provides better survival than other treatments simply because the operation uses robotic technology. In the ProtecT trial population of men with PSA-detected localised prostate cancer, prostatectomy, radiotherapy and active monitoring were all associated with low prostate cancer mortality at 15 years.
Your choice depends on your cancer, health, age and personal priorities. Robotic surgery is simply a method of performing prostatectomy, rather than a guarantee of better survival.
Myth vs Fact
| Myth | Fact |
| Robotic prostatectomy guarantees that prostate cancer will never return. | Surgery can provide long-term cancer control, but some men develop biochemical recurrence and require further monitoring or treatment. |
| A 98% survival rate means every patient has a 98% chance of surviving. | Published survival figures describe groups of patients and cannot predict exactly what will happen to one individual. |
| A rising PSA means the prostate cancer has already spread. | PSA recurrence can occur before cancer is detectable elsewhere and does not automatically mean metastatic disease. |
| Positive surgical margins mean the operation has failed. | Positive margins can increase recurrence risk, but they do not mean that metastatic disease or prostate cancer death is inevitable. |
| Robotic surgery always gives better cancer survival than radiotherapy. | The most appropriate treatment depends on cancer risk, health and individual priorities; robotic surgery does not guarantee superior survival. |
| Everyone has the same outlook after robotic prostatectomy. | Stage, Grade Group, PSA, lymph-node involvement, pathology and general health can all affect long-term outcomes. |
How Can Your Personal Survival Outlook Be Estimated?
Your personal outlook depends on your stage, Grade Group and PSA, along with MRI findings and other test results. After surgery, your pathology results, including margins, lymph nodes and seminal vesicle involvement, can give you a clearer estimate.
Your age and general health also affect overall survival. Rather than relying on an average survival figure, you should ask your specialist how your individual results compare with published outcomes.
Key Takeaways
- Long-term robotic prostatectomy studies report prostate cancer-specific survival of around 98–99% at 10 years and approximately 97–98% at 15 years in studied populations.
- Survival varies considerably according to cancer risk, stage, Grade Group, PSA and pathological findings.
- PSA recurrence does not automatically mean that prostate cancer has spread or that survival will be poor.
- Overall survival is lower than prostate cancer-specific survival because it includes deaths from other causes.
- Published survival percentages describe groups of patients and cannot predict an individual outcome.
- Your specialist can give you a more personalised outlook using your cancer characteristics and results after surgery.
Frequently Asked Questions
1. What is the survival rate after robotic prostate surgery?
Long-term studies have reported prostate cancer-specific survival of around 98–99% at 10 years after robotic prostate surgery in some groups. Your individual survival outlook depends on factors such as your cancer stage, Grade Group, PSA level and whether lymph nodes are involved.
2. What is the 15-year survival rate after robotic prostatectomy?
Some long-term studies have reported approximately 97–98% prostate cancer-specific survival at 15 years after robot-assisted radical prostatectomy. However, outcomes can be less favourable if you have high-risk or more advanced prostate cancer.
3. Does robotic prostate surgery cure prostate cancer?
Radical prostatectomy can be a potentially curative treatment for appropriately selected men with localised prostate cancer. However, recurrence can still occur, so long-term PSA monitoring remains important after surgery.
4. Does prostate cancer stage affect survival after robotic surgery?
Yes. Your cancer stage is an important factor in your long-term outlook. Studies have reported higher 15-year prostate cancer-specific survival for men with cancer confined to the prostate than for those with more advanced disease, particularly when the seminal vesicles are involved.
5. Does Grade Group affect survival after robotic prostate surgery?
Yes. A higher Grade Group generally indicates more aggressive prostate cancer and is associated with a greater risk of recurrence and progression. However, your Grade Group needs to be considered alongside your PSA, stage, lymph-node status and other pathological findings.
6. Does a high PSA reduce your survival chances after robotic prostatectomy?
A higher PSA before surgery can be associated with a greater risk of recurrence and less favourable long-term outcomes. However, PSA alone cannot determine your prognosis, so your doctor will consider it alongside your Grade Group, MRI findings and cancer stage.
7. Is PSA recurrence the same as prostate cancer spreading?
No. A rise in PSA after surgery can indicate biochemical recurrence, but it does not automatically mean that your cancer has spread or that you will die from prostate cancer. Recurrence can sometimes be treated before the cancer becomes metastatic.
8. Do positive surgical margins mean that prostate cancer will return?
Not necessarily. A positive surgical margin can increase your risk of biochemical recurrence, but it does not automatically mean that you will develop metastatic cancer. Your postoperative PSA, tumour stage, Grade Group and characteristics of the margin all help determine your individual risk.
9. What happens to survival if prostate cancer has spread to the lymph nodes?
Lymph-node involvement generally indicates higher-risk disease and can make cancer control with surgery alone less likely. However, long-term survival can still be favourable for some men, particularly when additional treatments such as radiotherapy or hormone therapy are appropriate.
10. Is robotic surgery better for survival than other prostate cancer treatments?
Not necessarily. For localised prostate cancer, prostatectomy, radiotherapy and active monitoring can all provide high prostate cancer-specific survival in appropriately selected men. Your decision should also take into account your cancer characteristics, overall health, possible side effects and personal priorities.
Final Thoughts: Understanding Your Survival Outlook After Robotic Prostate Surgery
If you are considering robotic prostate surgery, the long-term survival figures can be encouraging, particularly when your prostate cancer is localised or lower risk. Your individual outlook still depends on your PSA, Grade Group, cancer stage, lymph-node involvement, surgical margins and postoperative PSA, so a general survival percentage cannot predict exactly what will happen to you.
If you are considering robotic prostate surgery in London and would like specialist advice, you can contact our team at Prostate Clinic London to discuss your options and arrange a consultation tailored to your individual needs.
References:
- Diaz, M., Peabody, J.O., Kapoor, V., Sammon, J., Rogers, C.G., Stricker, H., Lane, Z., Gupta, N., Bhandari, M. and Menon, M. (2015) ‘Oncologic outcomes at 10 years following robotic radical prostatectomy’, European Urology, 67(6), pp. 1168–1176. Available at: https://www.sciencedirect.com/science/article/pii/S0302283814005995
- Sood, A. et al. (2023) ‘15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer’, Prostate Cancer and Prostatic Diseases, 26, pp. 778–786. Available at: https://www.nature.com/articles/s41391-023-00674-2
- Falagario, U.G. et al. (2024) ‘Prostate cancer-specific and all-cause mortality after robot-assisted radical prostatectomy: 20 years’ report from the European Association of Urology Robotic Urology Section Scientific Working Group’, European Urology Oncology, 7(4), pp. 705–712. Available at: https://www.sciencedirect.com/science/article/pii/S2588931123001682
- Hamdy, F.C. et al. (2023) ‘Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer’, The New England Journal of Medicine, 388(17), pp. 1547–1558. Available at: https://researchcollaborations.elsevier.com/en/publications/fifteen-year-outcomes-after-monitoring-surgery-or-radiotherapy-fo/
- National Institute for Health and Care Excellence (NICE) (2019, updated 2021) Prostate cancer: diagnosis and management. NICE guideline NG131. Available at: https://www.nice.org.uk/guidance/ng131
- Cancer Research UK (2025) Survival for prostate cancer. Last reviewed 11 June 2025. Available at: https://www.cancerresearchuk.org/about-cancer/prostate-cancer/survival